Stratos Wealth Advisors LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 3,174 shares of the biopharmaceutical company’s stock, valued at approximately $273,000.
A number of other large investors also recently modified their holdings of GILD. Premier Fund Managers Ltd boosted its holdings in Gilead Sciences by 62.0% in the third quarter. Premier Fund Managers Ltd now owns 8,746 shares of the biopharmaceutical company’s stock valued at $552,000 after acquiring an additional 3,346 shares during the last quarter. Avantax Planning Partners Inc. bought a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $229,000. Brookstone Capital Management lifted its holdings in Gilead Sciences by 5.7% during the 3rd quarter. Brookstone Capital Management now owns 169,160 shares of the biopharmaceutical company’s stock worth $11,061,000 after purchasing an additional 9,145 shares during the last quarter. Gladstone Institutional Advisory LLC lifted its holdings in Gilead Sciences by 8.5% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 15,099 shares of the biopharmaceutical company’s stock worth $931,000 after purchasing an additional 1,180 shares during the last quarter. Finally, Moody National Bank Trust Division raised its holdings in Gilead Sciences by 27.7% in the 3rd quarter. Moody National Bank Trust Division now owns 29,923 shares of the biopharmaceutical company’s stock valued at $1,846,000 after acquiring an additional 6,492 shares in the last quarter. 78.72% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on GILD shares. Wells Fargo & Company boosted their price objective on Gilead Sciences from $75.00 to $90.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 3rd. Barclays upped their target price on Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a report on Wednesday, January 18th. Piper Sandler raised their price target on Gilead Sciences from $111.00 to $112.00 and gave the stock an “overweight” rating in a report on Friday, February 3rd. Royal Bank of Canada cut their price target on Gilead Sciences from $87.00 to $86.00 and set a “sector perform” rating for the company in a report on Monday, March 6th. Finally, Bank of America reiterated a “neutral” rating and issued a $85.00 price objective on shares of Gilead Sciences in a research report on Tuesday, December 13th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $89.40.
Gilead Sciences Price Performance
Gilead Sciences (NASDAQ:GILD – Get Rating) last posted its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.17. Gilead Sciences had a net margin of 16.83% and a return on equity of 44.46%. The firm had revenue of $7.39 billion for the quarter, compared to the consensus estimate of $6.63 billion. During the same period last year, the firm posted $0.69 EPS. The company’s revenue was up 2.0% on a year-over-year basis. Equities analysts forecast that Gilead Sciences, Inc. will post 6.86 EPS for the current fiscal year.
Gilead Sciences Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 30th. Shareholders of record on Wednesday, March 15th were given a dividend of $0.75 per share. The ex-dividend date of this dividend was Tuesday, March 14th. This represents a $3.00 dividend on an annualized basis and a yield of 3.62%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.73. Gilead Sciences’s payout ratio is presently 82.19%.
Insider Transactions at Gilead Sciences
In other Gilead Sciences news, insider Merdad Parsey sold 6,126 shares of the business’s stock in a transaction that occurred on Monday, March 13th. The shares were sold at an average price of $78.99, for a total transaction of $483,892.74. Following the completion of the sale, the insider now directly owns 70,130 shares in the company, valued at $5,539,568.70. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.16% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Featured Articles
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze, Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- Walmart Shares Jump on Evercore Analyst Upgrade
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
